10-K: Intelligent Bio Solutions Inc. Files 10-K, Details Financials and Operations

Intelligent Bio Solutions Inc. released its annual 10-K filing, outlining its financial status, operational achievements, and future strategies, including progress on FDA approval and global expansion.

Summary

• Intelligent Bio Solutions Inc. (INBS) has filed its annual 10-K report, detailing its financial performance and operational activities for the fiscal year ended June 30, 2024.
• The company reported a revenue of $3.11 million, a significant increase from $1.26 million in the previous year, driven by expanded customer base and market penetration.
• Gross profit also saw a substantial rise, reaching $1.43 million compared to $0.33 million in the prior year, with a gross profit margin of 45.81%.
• The company's net loss was $10.16 million, a slight improvement from $10.63 million in the previous year.
• INBS raised approximately $14.56 million through various offerings during the fiscal year, ending with a cash balance of $6.30 million.
• The company is progressing with its FDA 510(k) clinical study plan, having completed the in-clinic portion of its Pharmacokinetic (PK) study and expects to complete the full PK study in the third calendar quarter of 2024.
• INBS has expanded its global footprint, including entry into the New Zealand market and new partnerships in various regions.
• The company's Intelligent Fingerprinting Drug Screening System has seen continued customer growth, with over 25,000 tests completed by one customer alone.
• The company is also in early-stage discussions regarding the potential restructuring of future licensing of its Biosensor Platform Technology with the University of Newcastle.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is strong revenue growth and progress in product development, the going concern warning and material weaknesses in internal controls raise significant concerns. The sentiment is neutral to slightly negative due to these risks.

Positives

• Significant revenue growth of 147.58% year-over-year.
• Substantial increase in gross profit by 336.41% year-over-year.
• Improved gross profit margin from 25.99% to 45.81%.
• Successful capital raising of $14.56 million.
• Successful completion of the in-clinic portion of the Pharmacokinetic (PK) study.
• Expansion into new markets, including New Zealand.
• Recertification for the latest ISO 13485: 2016 quality management system standard.
• New partnerships and customer growth demonstrate market acceptance of the company's technology.

Negatives

• The company continues to operate at a net loss, although it has decreased slightly from the previous year.
• The company's independent auditor has raised substantial doubt about its ability to continue as a going concern.
• The company is still in early-stage discussions regarding the potential restructuring of future licensing of its Biosensor Platform Technology.
• The company relies on third parties for confirmatory tests and single-source suppliers for certain components, which could lead to supply chain vulnerabilities.
• The company has identified material weaknesses in its internal control over financial reporting.

Risks

• The company may need to raise additional capital to fund operations, and there is no guarantee that such capital will be available on favorable terms.
• The company's independent auditor has included an explanatory paragraph relating to the company's ability to continue as a going concern.
• The company relies on third parties for confirmatory tests and single-source suppliers for certain components, which could lead to supply chain vulnerabilities.
• The company is subject to risks associated with international relationships, including regulatory requirements and currency exchange rates.
• The company's products may contain undetected errors, which could limit its ability to provide its products and services.
• The company is subject to the risk of reliance on third parties to conduct clinical evaluation work.
• The company depends on intellectual property licensed from the Licensor for its BPT related products, and any absence of legal effect of the license or dispute over the license would significantly harm our BPT related business.
• The company may not be able to satisfy the continued listing requirements of the Nasdaq Capital Market.
• The company has identified material weaknesses in its internal control over financial reporting.

Future Outlook

The company expects to complete the full PK study in the third calendar quarter of 2024 and plans to submit its 510(k) application by the end of 2024, with a planned entry into the United States market in 2025. The company also aims to continue growth in new markets, offering an alternative and innovative solution that places a strong emphasis on operational efficiency, fitness for duty, employee privacy and dignity.

Management Comments

• The company looks to continue this momentum and expand into new customer segments and geographical regions throughout the APAC Region, Europe, South America and the United Arab Emirates.
• The Company aims to continue growth in new markets, offering an alternative and innovative solution that places a strong emphasis on operational efficiency, fitness for duty, employee privacy and dignity.

Industry Context

The company operates in the competitive medical device industry, focusing on non-invasive testing solutions. The company's expansion into new markets and partnerships aligns with the broader industry trend of increasing demand for point-of-care diagnostics and drug screening solutions. The company's focus on fingerprint sweat-based technology provides a unique approach compared to traditional urine and saliva-based tests.

Comparison to Industry Standards

• The company's revenue growth of 147.58% significantly exceeds the average growth rate in the medical device industry, which typically ranges from 5% to 15% annually, indicating strong market traction.
• The gross profit margin of 45.81% is competitive within the medical device sector, where margins can vary widely depending on the product type and market segment. Companies like Abbott and Medtronic often report gross margins between 60% and 70%, while smaller, growth-focused companies may have lower margins.
• The company's focus on fingerprint sweat-based technology is a differentiator compared to competitors like Alere (now Abbott Rapid Diagnostics) and OraSure Technologies, which primarily focus on urine and oral fluid-based testing. This unique approach could provide a competitive advantage in terms of non-invasiveness and ease of use.
• The company's expansion into new markets, such as New Zealand, is a common strategy for medical device companies seeking growth, similar to how companies like Roche and Siemens Healthineers expand their global reach.
• The company's progress with FDA 510(k) clearance is a critical step for entering the U.S. market, which is a major milestone for medical device companies. The timeline for FDA approval can vary, but the company's target of 2025 is within a reasonable timeframe for similar devices.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently engaged in any material legal proceedings.

Related Party Transactions

• Spiro Sakiris, the Chief Financial Officer, purchased 112,727 units in the October 2023 Offering.
• Christopher Towers, a former member of the Board, purchased 9,090 units in the October 2023 Offering.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Employees may benefit from the company's growth and expansion.
• Customers may benefit from the company's innovative and accessible testing solutions.
• Suppliers may benefit from increased demand for the company's products.
• Creditors may be impacted by the company's financial performance and ability to repay debts.

Next Steps

• Complete the full Pharmacokinetic (PK) study in the third calendar quarter of 2024.
• Submit the FDA 510(k) application by the end of 2024.
• Plan entry into the United States market in 2025.
• Continue expansion into new customer segments and geographical regions.
• Restructure future licensing of BPT with the University of Newcastle.

Key Dates

Keywords

Intelligent Bio Solutions, Drug Screening, Biosensor Platform, FDA 510(k), Pharmacokinetic Study, ISO 13485, Medical Technology, Point of Care Testing, Fingerprint Diagnostics, Global Expansion